Heron Therapeutics/$HRTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Heron Therapeutics
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
- Ticker
- $HRTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 128
- Headquarters
- Cary, United States
- Website
- www.herontx.com
HRTX Metrics
BasicAdvanced
$66M
-
-$0.18
1.66
-
Price and volume
Market cap
$66M
Beta
1.66
52-week high
$1.58
52-week low
$0.30
Average daily volume
2.6M
Financial strength
Current ratio
2.494
Quick ratio
1.435
Long term debt to equity
2,144.673
Total debt to equity
2,147.568
Interest coverage (TTM)
-0.76%
Profitability
EBITDA (TTM)
-8.731
Gross margin (TTM)
61.93%
Net profit margin (TTM)
-22.52%
Operating margin (TTM)
-7.19%
Revenue per employee (TTM)
$1,180,000
Management effectiveness
Return on assets (TTM)
-2.80%
Return on equity (TTM)
334.63%
Valuation
Price to revenue (TTM)
0.428
Price to book
11.32
Price to tangible book (TTM)
11.32
Price to free cash flow (TTM)
-5.33
Free cash flow yield (TTM)
-18.76%
Free cash flow per share (TTM)
-0.066
Growth
Revenue change (TTM)
0.99%
Earnings per share change (TTM)
2,307.50%
3-year revenue growth (CAGR)
8.62%
3-year earnings per share growth (CAGR)
-45.89%
10-year earnings per share growth (CAGR)
-25.71%
What the Analysts think about HRTX
Analyst ratings (Buy, Hold, Sell) for Heron Therapeutics stock.
Analyst projections of the future price of Heron Therapeutics stock.
HRTX Financial Performance
Revenues and expenses
HRTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
HRTX News
AllArticlesVideos
Funds containing HRTX
Fund name | Fund size | $HRTX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.